Neuberger Berman Group LLC Has $86.09 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Neuberger Berman Group LLC lessened its holdings in Omnicell, Inc. (NASDAQ:OMCLGet Rating) by 1.7% in the 1st quarter, HoldingsChannel.com reports. The firm owned 664,805 shares of the company’s stock after selling 11,610 shares during the quarter. Neuberger Berman Group LLC’s holdings in Omnicell were worth $86,086,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Synovus Financial Corp increased its stake in Omnicell by 0.5% in the 4th quarter. Synovus Financial Corp now owns 15,312 shares of the company’s stock valued at $2,760,000 after buying an additional 77 shares during the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of Omnicell by 0.5% in the first quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the company’s stock valued at $2,567,000 after purchasing an additional 100 shares during the last quarter. Maryland State Retirement & Pension System boosted its position in Omnicell by 0.6% during the first quarter. Maryland State Retirement & Pension System now owns 17,621 shares of the company’s stock worth $2,282,000 after purchasing an additional 103 shares during the period. Stephens Inc. AR lifted its position in Omnicell by 3.7% during the fourth quarter. Stephens Inc. AR now owns 3,082 shares of the company’s stock valued at $556,000 after purchasing an additional 109 shares during the last quarter. Finally, Great West Life Assurance Co. Can raised its stake in shares of Omnicell by 0.4% during the first quarter. Great West Life Assurance Co. Can now owns 37,956 shares of the company’s stock worth $5,036,000 after acquiring an additional 144 shares in the last quarter.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $95.27 on Friday. The business’s 50-day simple moving average is $107.22 and its 200-day simple moving average is $115.13. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.71 and a current ratio of 2.11. Omnicell, Inc. has a 52 week low of $94.78 and a 52 week high of $187.29. The firm has a market cap of $4.22 billion, a price-to-earnings ratio of 75.61, a P/E/G ratio of 2.67 and a beta of 1.06.

Omnicell (NASDAQ:OMCLGet Rating) last released its earnings results on Thursday, August 4th. The company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.01). Omnicell had a return on equity of 10.37% and a net margin of 4.82%. The company had revenue of $331.39 million for the quarter, compared to the consensus estimate of $339.45 million. During the same quarter in the previous year, the company posted $0.71 EPS. The business’s revenue was up 21.5% on a year-over-year basis. As a group, equities research analysts expect that Omnicell, Inc. will post 2.7 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Randall A. Lipps sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $111.04, for a total transaction of $1,443,520.00. Following the completion of the sale, the chief executive officer now owns 302,049 shares in the company, valued at approximately $33,539,520.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO Peter J. Kuipers sold 11,000 shares of the stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $105.93, for a total transaction of $1,165,230.00. Following the sale, the chief financial officer now owns 61,326 shares in the company, valued at $6,496,263.18. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Randall A. Lipps sold 13,000 shares of the stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $111.04, for a total transaction of $1,443,520.00. Following the completion of the sale, the chief executive officer now directly owns 302,049 shares of the company’s stock, valued at $33,539,520.96. The disclosure for this sale can be found here. Insiders sold a total of 39,500 shares of company stock worth $4,287,245 in the last three months. Company insiders own 2.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on OMCL. Bank of America initiated coverage on shares of Omnicell in a research report on Friday, September 9th. They set a “buy” rating and a $120.00 price objective on the stock. BTIG Research cut their price objective on shares of Omnicell from $190.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, July 27th. SVB Leerink initiated coverage on shares of Omnicell in a research report on Friday, July 15th. They set a “market perform” rating and a $124.00 target price on the stock. KeyCorp initiated coverage on shares of Omnicell in a research report on Thursday. They set an “overweight” rating and a $130.00 price objective for the company. Finally, Piper Sandler decreased their target price on shares of Omnicell from $162.00 to $150.00 and set an “overweight” rating on the stock in a research report on Monday, August 8th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell currently has a consensus rating of “Moderate Buy” and a consensus target price of $151.71.

Omnicell Profile

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Read More

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCLGet Rating).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.